Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 3/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 4/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | AHCY | P23526 | 1/20 | 0.32 |
| ▸ | PI4KA | P42356 | 4/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.31 |
| ▸ | XDH | P47989 | 2/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1094884 | 1.00 | RET (0.42) | RETKDRMETEGFRERBB2 | |
| SCHEMBL890570 | 0.71 | MAPT (0.36) | KDM4EL3MBTL1LMNAALOX15HTT | |
| SCHEMBL890571 | 0.71 | MAPT (0.36) | KDM4EL3MBTL1LMNAALOX15HTT | |
| SCHEMBL16583459 | 0.71 | HPGD (0.39) | RETKDRMETKDM4EL3MBTL1 | |
| SCHEMBL16583458 | 0.71 | HPGD (0.39) | RETKDRMETKDM4EL3MBTL1 | |
| SCHEMBL1105337 | 0.71 | GALR3 (0.50) | EGFRLMNA | |
| SCHEMBL12891981 | 0.67 | PI4KA (0.34) | RETKDRMETL3MBTL1PI4KA | |
| SCHEMBL17073884 | 0.64 | EGFR (0.36) | RETKDREGFRERBB2 | |
| SCHEMBL8386307 | 0.64 | — | — | |
| SCHEMBL20544102 | 0.62 | NPC1 (0.39) | KDM4EL3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367825-B2 | Substituted pyrimidinyl oxime kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-05 | — | — | US | disclosed |
| US-8278446-B2 | reacting 4-amino-6-chloro-pyrimidine-5-carbaldehyde with 4-benzyloxy-3-chloro-phenylamine in an aqueous solvent and a catalytic amount of hydrochloric acid, to providw 4-amino-6-(4-benzyloxy-3-chloro-phenylamino)-pyrimidine-5-carbaldehyde, then oximination with (2-morpholin-4-yl-ethyl)-hydroxylamine | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-10-02 | — | — | US | disclosed |
| US-20120157412-A1 | Substituted Pyrimidinyl Oxime Kinase Inhibitors | BATTISTA KATHLEEN A (US) | 2012-06-21 | — | — | US | disclosed |
| US-8153791-B2 | substituted pyrimidine compoundssuch as 4-amino-6-(3-chloro-4-fluoro-phenylamino)-pyrimidine-5-carbaldehyde O-methyl oxime, used for treating, preventing or ameliorating a chronic or acute protein kinase mediated diseasea, disorders or conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-10 | — | — | US | disclosed |
| US-8013153-B2 | Substituted pyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-09-06 | — | — | US | disclosed |
| WO-2009055299-A1 | SUBSTITUTED PYRIMIDINE-5-CARBOXAMIDE AND 5-CARBOXYLIC ESTER KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | WO | disclosed |
| US-20090111810-A1 | SUBSTITUTED PYRIMIDINE-5-CARBOXAMIDE AND 5-CARBOXYLIC ESTER KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| US-20080249304-A1 | PROCESS FOR PREPARING SUBSTITUTED DIAMINOPYRIMIDINE OXIMES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-09 | — | — | US | disclosed |
| WO-2008073519-A1 | PROCESS FOR PREPARING SUBSTITUTED DIAMINOPYRIMIDINE OXIMES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-06-19 | — | — | WO | disclosed |
| US-20070270425-A1 | SUBSTITUTED PYRIMIDINYL OXIME KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-22 | — | — | US | disclosed |
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | US | disclosed |
| WO-2007109783-A2 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007081630-A2 | SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157412-A1 | Substituted Pyrimidinyl Oxime Kinase Inhibitors | MAP3K2, MAP3K1, MAP3K20 | RET 536/4885KDR 797/4885MET 815/4885 |
| US-20090111810-A1 | SUBSTITUTED PYRIMIDINE-5-CARBOXAMIDE AND 5-CARBOXYLIC ESTER KINASE INHIBITORS | MAP3K5, FLT3, MAP3K19 | RET 58/4885KDR 460/4885MET 550/4885 |
| US-20070270425-A1 | SUBSTITUTED PYRIMIDINYL OXIME KINASE INHIBITORS | MAP3K2, MAP3K1, MAP3K20 | RET 536/4885KDR 797/4885MET 815/4885 |
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | DTYMK, TK1, DCK | RET 577/4885KDR 1975/4885MET 1781/4885 |
| US-20080249304-A1 | PROCESS FOR PREPARING SUBSTITUTED DIAMINOPYRIMIDINE OXIMES | DHPS, DPYD, DCPS | RET 993/4885KDR 1277/4885MET 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.